Fulcrum Therapeutics experienced sharp downward stock valuation drops following major clinical pipeline adjustments, most notably the announcement that the company decided to completely discontinue the development of its lead drug candidate, pociredir, for sickle-cell disease following unresolved regulatory concerns raised during communications with the U.S. Food and Drug Administration. Because pociredir represented the most advanced asset in its clinical pipeline, its sudden termination removed a primary commercial growth catalyst, triggering heavy sell volumes and negative sentiment across public equity markets.